Skip to content

Study · Systematic review · 2021

3 results

The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.

Tandon S, Ayis S, Hopkins D, Hopkins D, Harding S, Stadler M

Diabetes, obesity & metabolism2 Nov 2020Cited by 20 (Europe PMC)

PMID33026152 (opens in a new tab)DOI10.1111/dom.14221 (opens in a new tab)PepBankPUB-33026152
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 1 diabetes, a meta-analysis found that liraglutide 0.6 mg was associated with a significant body weight reduction (mean difference -2.22 kg).

    In plain wordsIn adults with type 1 diabetes, liraglutide 0.6 mg was linked to weight loss in pooled trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight, mean difference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6 mgAs given in this study (human).

    Measurements

    mean difference body weight
    −2.22 kg
    liraglutide 0.6 mg

    Source sentences

    Summary
    The GLP-1 receptor agonist liraglutide 0.6 mg (mean difference [MD]: -2.22 kg [95% CI: -2.55 to -1.90])
    1 context sentence
    Summary · context
    Meta-analyses were performed for 16 randomized controlled trials (RCTs).
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 1 diabetes, a meta-analysis found that liraglutide 1.2 mg was associated with a significant body weight reduction (mean difference -3.74 kg).

    In plain wordsIn adults with type 1 diabetes, liraglutide 1.2 mg was linked to weight loss in pooled trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight, mean difference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2 mgAs given in this study (human).

    Measurements

    mean difference body weight
    −3.74 kg
    liraglutide 1.2 mg

    Source sentences

    Summary
    1.2 mg (MD: -3.74 kg [95% CI: -4.16 to -3.33])
    1 context sentence
    Summary · context
    Meta-analyses were performed for 16 randomized controlled trials (RCTs).
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 1 diabetes, a meta-analysis found that liraglutide 1.8 mg was associated with a significant body weight reduction (mean difference -4.85 kg).

    In plain wordsIn adults with type 1 diabetes, liraglutide 1.8 mg was linked to weight loss in pooled trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight, mean difference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    mean difference body weight
    −4.85 kg
    liraglutide 1.8 mg

    Source sentences

    Summary
    1.8 mg (MD: -4.85 kg [95% CI: -5.29 to -4.41])
    1 context sentence
    Summary · context
    Meta-analyses were performed for 16 randomized controlled trials (RCTs).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.